Savara presents Phase 3 data showing MOLBREEVI improves lung function in autoimmune PAP
SVRA•Savara said its Phase 3 IMPALA-2 trial met its primary endpoint, with a 6-point DLCO advantage over placebo at week 24 and a 6.9-point advantage at week 48. The FDA decision date for MOLBREEVI was delayed, with no revised action date.
1. Trial results
The Phase 3 IMPALA-2 trial met its primary lung-function endpoint at week 24, showing a 6-point DLCO advantage over placebo (p=0.0007). The advantage reached 6.9 points at week 48 (p=0.0008), and respiratory quality-of-life scores improved significantly at week 24 (p=0.0072). Treatment discontinuation was 3%, with none attributed to drug-related adverse events.
2. FDA decision delayed
Savara’s November 22, 2026, FDA decision date for MOLBREEVI in autoimmune pulmonary alveolar proteinosis was delayed; no revised action date was provided.




